AbbVie Surges on Phase 3 Win; Nxera Hits Milestone

AbbVie ($ABBV) announced positive Phase 3 results from the EPCORE DLBCL-4 trial evaluating epcoritamab, a T-cell engaging bispecific antibody, plus lenalidomide compared to rituximab plus gemcitabine plus oxaliplatin in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. Based on topline results from the prespecified primary analysis, the trial met its primary endpoint. The announcement contributed to a five-day winning streak for $ABBV, with cumulative gains amounting to 17% and market cap surging by approximately $65B over the period to $448B. $ABBV also recently received FDA approval for Skyrizi for pediatric patients with psoriasis aged six years and older, expanding the drug's addressable market. Bristol Myers Squibb ($BMY) closed at $58.56, marking a gain of 1.81% from the previous day.

Nxera Pharma announced it reached a milestone triggering a $10M payment from $ABBV under their collaboration targeting neurological diseases. This marks the fourth R&D milestone achieved under the collaboration and the second in 2026, reflecting steady progress of development under the agreement. Under the terms, Nxera is eligible to receive up to $1.2B in potential option, development, and commercial milestones, in addition to tiered royalties based on sales. The collaboration demonstrates continued momentum in neurology-focused drug development partnerships within Big Pharma.

Eli Lilly ($LLY) continued to draw investor attention for its dominance in the GLP-1 weight loss market, with multiple analyses examining the stock's valuation and growth trajectory. Analysts highlighted the company's strong cash flow generation and its efforts to build an AI-native drug discovery and manufacturing platform beyond the weight loss franchise. The focus on $LLY reflects broader market interest in obesity therapeutics as a sustained growth driver for pharmaceutical companies. Investor discussions centered on whether to chase the recent breakout in $LLY shares and the potential five-year return profile from current levels.

Intuitive Surgical ($ISRG) was highlighted for its Quintuple Aim strategy driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth. Stereotaxis ($STXS) is navigating a pivotal product transition, with fresh regulatory wins and a transformational acquisition reshaping its commercial runway, even as near-term results reflect the costs of that transition. Analysts described $STXS as having a compelling razor/razor blade ecosystem serving as a driver of sustainable growth, noting significant hedge fund backing and attractive upside potential. The surgical robotics segment continues to demonstrate innovation-driven differentiation and adoption momentum.

A market research study on the global hematologic malignancies testing market indicated the sector was valued at approximately $3.28B in 2025 and is expected to reach $3.72B in 2026, with projections pointing to $12.47B by 2035 at a compound annual growth rate of 14.4% between 2026 and 2035. Key market players listed in the report include Abbott Laboratories and Thermo Fisher Scientific ($TMO), among others. The diagnostics segment continues to benefit from advances in precision medicine and molecular testing capabilities for blood cancers.

Amgen ($AMGN) closed at $360.55, with returns of 3.9% over the past week, 7.1% over the past month, 10.0% year to date, 27.8% over one year, 75.7% over three years, and 73.2% over five years. Analysts assessed whether $AMGN shares still offer value at current levels amid the strong run and mixed valuation signals. Pfizer ($PFE) traded at $25.08, with a trailing P/E of 19.15 and forward P/E of 8.50 according to available data. The biotech sector showed defensive characteristics with health care sectors demonstrating strength amid mixed broader equity market performance.

UnitedHealth Group ($UNH) was featured in top research reports highlighting growth drivers, key risks, and analyst views shaping the outlook. The healthcare giant is scheduled to release second-quarter results on July 16, with investors assessing whether to position ahead of the earnings event. $UNH continues to serve as a bellwether for managed care trends and healthcare utilization patterns across the sector.